(NASDAQ: ABSI) Absci's forecast annual revenue growth rate of 196.21% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Absci's revenue in 2026 is $1,836,000.On average, 12 Wall Street analysts forecast ABSI's revenue for 2026 to be $1,160,869,047, with the lowest ABSI revenue forecast at $351,409,996, and the highest ABSI revenue forecast at $4,419,908,338. On average, 12 Wall Street analysts forecast ABSI's revenue for 2027 to be $3,533,432,189, with the lowest ABSI revenue forecast at $458,360,865, and the highest ABSI revenue forecast at $16,635,069,475.
In 2028, ABSI is forecast to generate $7,806,945,679 in revenue, with the lowest revenue forecast at $611,147,820 and the highest revenue forecast at $26,779,811,469.